Pfizer Inc. CEO Ian Read recently affirmed Pfizer's commitment to emerging markets, choosing to keep its established products unit in-house even as he looks to divest non-core assets like the animal health and nutrition business units. Just one week after the announcement of Read's plan, Salomon Azoulay, Pfizer's senior VP for medical & development emerging markets, and Pfizer China Vaccines Lead Bing Yan sat down with PharmAsia News' Shanghai Bureau to talk about Pfizer's blockbuster vaccines Prevenar and Prevenar 13 - marketed in the U.S. as Prevnar - in what will be the world's largest vaccines market. Azoulay was in town to explore partnerships in China, a topic he also discusses in this interview, as well as the importance of physician education in emerging markets.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
